26
|
Wang L, Xu J, Han Y, Jin H, Hong B, Jin D, Gong J, Peng X, Ge H, Wang X. Nanocasting synthesis and highly-improved toluene gas-sensing performance of Co3O4 nanowires with high-valence Sn-doping. Chem Phys 2022. [DOI: 10.1016/j.chemphys.2022.111573] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Bhatt AS, Varshney AS, Goodrich EL, Gong J, Ginder C, Senman BC, Johnson M, Butler K, Woolley AE, de Lemos JA, Morrow DA, Bohula EA. Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. J Am Heart Assoc 2022; 11:e024451. [PMID: 35470683 PMCID: PMC9238583 DOI: 10.1161/jaha.121.024451] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Background Early reports from the COVID-19 pandemic identified coronary thrombosis leading to ST-segment-elevation myocardial infarction (STEMI) as a complication of COVID-19 infection. However, the epidemiology of STEMI in patients with COVID-19 is not well characterized. We sought to determine the incidence, diagnostic and therapeutic approaches, and outcomes in STEMI patients hospitalized for COVID-19. Methods and Results Patients with data on presentation ECG and in-hospital myocardial infarction were identified from January 14, 2020 to November 30, 2020, from 105 sites participating in the American Heart Association COVID-19 Cardiovascular Disease Registry. Patient characteristics, resource use, and clinical outcomes were summarized and compared based on the presence or absence of STEMI. Among 15 621 COVID-19 hospitalizations, 54 (0.35%) patients experienced in-hospital STEMI. Among patients with STEMI, the majority (n=40, 74%) underwent transthoracic echocardiography, but only half (n=27, 50%) underwent coronary angiography. Half of all patients with COVID-19 and STEMI (n=27, 50%) did not undergo any form of primary reperfusion therapy. Rates of all-cause shock (47% versus 14%), cardiac arrest (22% versus 4.8%), new heart failure (17% versus 1.4%), and need for new renal replacement therapy (11% versus 4.3%) were multifold higher in patients with STEMI compared with those without STEMI (P<0.050 for all). Rates of in-hospital death were 41% in patients with STEMI, compared with 16% in those without STEMI (P<0.001). Conclusions STEMI in hospitalized patients with COVID-19 is rare but associated with poor in-hospital outcomes. Rates of coronary angiography and primary reperfusion were low in this population of patients with STEMI and COVID-19. Adaptations of systems of care to ensure timely contemporary treatment for this population are needed.
Collapse
|
28
|
Tak YE, Boulay G, Lee L, Iyer S, Perry NT, Schultz HT, Garcia SP, Broye L, Horng JE, Rengarajan S, Naigles B, Volorio A, Sander JD, Gong J, Riggi N, Joung JK, Rivera MN. Genome-wide functional perturbation of human microsatellite repeats using engineered zinc finger transcription factors. CELL GENOMICS 2022; 2. [PMID: 35967079 PMCID: PMC9374162 DOI: 10.1016/j.xgen.2022.100119] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
29
|
Figueiredo JC, Ihenacho U, Merin NM, Hamid O, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Salvy SJ, Shirazipour CH, Caceres N, Finster LJ, Coleman B, Arnow HU, Florindez L, Sobhani K, Prostko JC, Frias EC, Stewart JL, Merchant A, Reckamp KL. SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment. Ann Oncol 2022; 33:109-111. [PMID: 34687893 PMCID: PMC8527840 DOI: 10.1016/j.annonc.2021.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/02/2021] [Accepted: 10/13/2021] [Indexed: 11/25/2022] Open
|
30
|
Aguilar M, Cavasonza LA, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Periodicities in the Daily Proton Fluxes from 2011 to 2019 Measured by the Alpha Magnetic Spectrometer on the International Space Station from 1 to 100 GV. PHYSICAL REVIEW LETTERS 2021; 127:271102. [PMID: 35061443 DOI: 10.1103/physrevlett.127.271102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 09/24/2021] [Accepted: 11/08/2021] [Indexed: 06/14/2023]
Abstract
We present the precision measurement of the daily proton fluxes in cosmic rays from May 20, 2011 to October 29, 2019 (a total of 2824 days or 114 Bartels rotations) in the rigidity interval from 1 to 100 GV based on 5.5×10^{9} protons collected with the Alpha Magnetic Spectrometer aboard the International Space Station. The proton fluxes exhibit variations on multiple timescales. From 2014 to 2018, we observed recurrent flux variations with a period of 27 days. Shorter periods of 9 days and 13.5 days are observed in 2016. The strength of all three periodicities changes with time and rigidity. The rigidity dependence of the 27-day periodicity is different from the rigidity dependences of 9-day and 13.5-day periods. Unexpectedly, the strength of 9-day and 13.5-day periodicities increases with increasing rigidities up to ∼10 GV and ∼20 GV, respectively. Then the strength of the periodicities decreases with increasing rigidity up to 100 GV.
Collapse
|
31
|
Gong J, Castro RRT, Caron JP, Bay CP, Hainer J, Opotowsky AR, Mehra MR, Maron BA, Di Carli MF, Groarke JD, Nohria A. Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum. ESC Heart Fail 2021; 9:293-302. [PMID: 34931762 PMCID: PMC8788025 DOI: 10.1002/ehf2.13761] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/04/2021] [Accepted: 11/24/2021] [Indexed: 01/09/2023] Open
Abstract
Aims The minute ventilation–carbon dioxide production relationship (VE/VCO2 slope) is widely used for prognostication in heart failure (HF) with reduced left ventricular ejection fraction (LVEF). This study explored the prognostic value of VE/VCO2 slope across the spectrum of HF defined by ranges of LVEF. Methods and results In this single‐centre retrospective observational study of 1347 patients with HF referred for cardiopulmonary exercise testing, patients with HF were categorized into HF with reduced (HFrEF, LVEF < 40%, n = 598), mid‐range (HFmrEF, 40% ≤ LVEF < 50%, n = 164), and preserved (HFpEF, LVEF ≥ 50%, n = 585) LVEF. Four ventilatory efficiency categories (VC) were defined: VC‐I, VE/VCO2 slope ≤ 29; VC‐II, 29 < VE/VCO2 slope < 36; VC‐III, 36 ≤ VE/VCO2 slope < 45; and VC‐IV, VE/VCO2 slope ≥ 45. The associations of these VE/VCO2 slope categories with a composite outcome of all‐cause mortality or HF hospitalization were evaluated for each category of LVEF. Over a median follow‐up of 2.0 (interquartile range: 1.9, 2.0) years, 201 patients experienced the composite outcome. Compared with patients in VC‐I, those in VC‐II, III, and IV demonstrated three‐fold, five‐fold, and eight‐fold increased risk for the composite outcome. This incremental risk was observed across HFrEF, HFmrEF, and HFpEF cohorts. Conclusions Higher VE/VCO2 slope is associated with incremental risk of 2 year all‐cause mortality and HF hospitalization across the spectrum of HF defined by LVEF. A multilevel categorical approach to the interpretation of VE/VCO2 slope may offer more refined risk stratification than the current binary approach employed in clinical practice.
Collapse
|
32
|
Wang C, Liu J, Peng X, Li J, Yang Y, Han Y, Xu J, Hong B, Gong J, Ge H, Wang X. FeSiCrB amorphous soft magnetic composites filled with Co2Z hexaferrites for enhanced effective permeability. ADV POWDER TECHNOL 2021. [DOI: 10.1016/j.apt.2021.11.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, Gong J, Senman BC, Silva D, Levangie MW, Berg DD, Yeh RW, de Lemos JA, Morrow DA, Kazi DS, Bohula EA. Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circ Heart Fail 2021; 14:e008477. [PMID: 34789004 DOI: 10.1161/circheartfailure.121.008477] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
34
|
Gong J, Drobni ZD, Alvi RM, Murphy SP, Sullivan RJ, Hartmann SE, Gilman HK, Lee H, Zubiri L, Raghu VK, Karp-Leaf RS, Zafar A, Zlotoff DA, Frigault MJ, Reynolds KL, Neilan TG. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 2021; 158:99-110. [PMID: 34662835 PMCID: PMC9010482 DOI: 10.1016/j.ejca.2021.09.010] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 08/11/2021] [Accepted: 09/10/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI. METHODS This was a retrospective study of 2854 patients who received ICIs at a single academic centre. VTE events, defined as a composite of deep vein thrombosis or pulmonary embolism, were identified by individual chart review and blindly adjudicated using standard imaging criteria. A self-controlled risk-interval design was applied with an 'at-risk period' defined as the two-year period after and the 'control period', defined as the two-year before treatment. The hazard ratio (HR) was calculated using a fixed-effect proportional hazards model. RESULTS Of the 2854 patients, 1640 (57.5%) were men; the mean age was 64 ± 13 years. The risk for VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI. The rate of VTE was > 4-fold higher after starting an ICI (HR 4.98, 95% CI 3.65-8.59, p < 0.001). There was a 5.7-fold higher risk for deep vein thrombosis (HR 5.70, 95% CI 3.79-8.59, p < 0.001) and a 4.75-fold higher risk for pulmonary embolism (HR 4.75, 95% CI 3.20-7.10, p < 0.001). Comparing patients with and without a VTE event, a history of melanoma and older age predicted lower risk of VTE, while a higher Khorana risk score, history of hypertension and history of VTE predicted higher risk. CONCLUSIONS The rate of VTE among patients on an ICI is high and increases after starting an ICI.
Collapse
|
35
|
Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann SE, Gilman HK, Raghu VK, Gongora C, Alvi R, Zubiri L, Nohria A, Sullivan RJ, Reynolds KL, Zlotoff DA, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis after treatment with immune checkpoint inhibitors (ICIs).
Purpose
To evaluate incidence of pericardial disease in patients treated with an ICI.
Methods
This was a retrospective study at a single academic center that compared 2842 consecutive patients who received ICIs with 2699 age- and cancer-type matched patients with metastatic disease who did not receive ICI (design 1). A pericardial event was defined as a composite outcome of pericarditis and new or worsening moderate or large pericardial effusion. The endpoints were obtained through chart review and were blindly adjudicated. To identify risk factors associated with a pericardial event, in a second analysis, we also compared patients who developed an event on an ICI to patients treated with an ICI who did not develop a pericardial event (design 2). Cox proportional hazard model and logistical regression analysis were performed to study the association between ICI use and pericardial disease as well as pericardial disease and mortality. An additional 6-week landmark analysis was performed to account for lead-time bias.
Results
There were 42 pericardial events in the patients treated with ICI (n=2842) over 193 days (interquartile range 64 to 411) with an incidence rate of 1.57 events per 100 person-years. There was a 4-fold increase in the risk for pericarditis or a pericardial effusion among patients on an ICI compared to controls not treated with ICI after adjusting for potential confounders (hazard ratio [HR] 4.37, 95% confidence interval [CI] 2.09–9.14, p<0.001). Patients who developed pericardial disease while on an ICI had a trend for increased all-cause mortality (HR 1.53, 95% CI 0.99–2.36, p=0.05) compared to those who did not develop pericardial disease. When comparing those who developed pericardial disease after ICI treatment to those who did not, a higher dose of corticosteroid pre-ICI (>0.7 mg/kg prednisone) was associated with increased risk of pericardial disease (HR 2.56, 95% CI 1.00–6.57, p=0.049).
Conclusions
ICI use was associated with an increased risk for development of pericardial disease among cancer patients and a pericardial event on an ICI was associated with a trend towards increased mortality.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): National Institutes of Health/National Heart, Lung, and Blood Institute; a gift from A. Curt Greer and Pamela Kohlberg
Collapse
|
36
|
Aguilar M, Cavasonza LA, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Erratum: Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen [Phys. Rev. Lett. 127, 021101 (2021)]. PHYSICAL REVIEW LETTERS 2021; 127:159901. [PMID: 34678040 DOI: 10.1103/physrevlett.127.159901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Indexed: 06/13/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.127.021101.
Collapse
|
37
|
Drobni ZD, Murphy SP, Alvi RM, Lee C, Gong J, Mosarla RC, Rambarat PK, Hartmann SB, Gilman HK, Zubiri L, Raghu VK, Sullivan RJ, Zafar A, Zlotoff DA, Sise ME, Guidon AC, Reynolds KL, Dougan M, Neilan TG. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. IMMUNOTHERAPY ADVANCES 2021; 1:ltab014. [PMID: 34541581 PMCID: PMC8444991 DOI: 10.1093/immadv/ltab014] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 05/23/2021] [Accepted: 06/14/2021] [Indexed: 12/17/2022] Open
Abstract
Objectives Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI). Skeletal myopathies are also a recognized statin-associated side effect. It is unknown whether concurrent use of statins and ICIs increases the risk of skeletal myopathies. Methods This was a retrospective cohort study of all patients who were treated with an ICI at a single academic institution (Massachusetts General Hospital, Boston, MA, USA). The primary outcome of interest was the development of a skeletal myopathy. The secondary outcome of interest was an elevated creatine kinase level (above the upper limit of normal). Results Among 2757 patients, 861 (31.2%) were treated with a statin at the time of ICI start. Statin users were older, more likely to be male and had a higher prevalence of cardiovascular and non-cardiovascular co-morbidities. During a median follow-up of 194 days (inter quartile range 65–410), a skeletal myopathy occurred in 33 patients (1.2%) and was more common among statin users (2.7 vs. 0.9%, P < 0.001). Creatine kinase (CK) elevation was present in 16.3% (114/699) and was higher among statin users (20.0 vs. 14.3%, P = 0.067). In a multivariable Cox model, statin therapy was associated with a >2-fold higher risk for skeletal myopathy (HR, 2.19; 95% confidence interval, 1.07–4.50; P = 0.033). Conclusion In this large cohort of ICI-treated patients, a higher risk was observed for skeletal myopathies and elevation in CK levels in patients undergoing concurrent statin therapy. Prospective observational studies are warranted to further elucidate the potential association between statin use and ICI-associated myopathies.
Collapse
|
38
|
Pang H, Lv J, Xu T, Li Z, Gong J, Liu Q, Wang Y, Wang J, Xia Z, Li Z, Li L, Zhu L. Incidence and risk factors of female urinary incontinence: a 4-year longitudinal study among 24 985 adult women in China. BJOG 2021; 129:580-589. [PMID: 34536320 PMCID: PMC9298368 DOI: 10.1111/1471-0528.16936] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 06/05/2021] [Accepted: 06/25/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To estimate the incidence of urinary incontinence (UI), including its subtypes stress UI (SUI), urgency UI (UUI) and mixed UI (MUI), and to examine risk factors for de novo SUI and UUI in Chinese women. DESIGN Nationwide longitudinal study. SETTING Six geographic regions of China. PARTICIPANTS Women aged ≥20 years old were included using a multistage, stratified, cluster sampling method. METHODS This study was conducted between May 2014 and March 2016, with follow up in 2018. Data on demographics, medical history, lifestyle and physiological and anthropometric information were collected. MAIN OUTCOME MEASUREMENTS Incidence, rate ratio (RR). RESULTS Analyses included 24 985 women (mean age 41.9 years).The follow-up response rate was 55.5%, median follow-up time was 3.7 years. The standardised incidences of UI, SUI, UUI and MUI were 21.2, 13.1, 3.0 and 5.1 per 1000 person-years, respectively. Risk factors for de novo SUI included delivery pattern (vaginal spontaneous delivery RR 2.12, 95% CI 1.62-2.78 and instrumental delivery RR 3.30, 95% CI 1.99-5.45), high body mass index (BMI) (overweight RR 1.52, 95% CI 1.33-1.74 and obesity RR 1.67, 95% CI 1.32-2.11), cigarette smoking (RR 1.54, 95% CI 1.12-2.12), chronic cough (RR 1.44, 95% CI 1.17-1.76), diabetes (RR 1.33, 95% CI 1.10-1.60) and older age (50-59 years RR 1.49, 95% CI 1.16-1.90 and 60-69 years RR 1.61, 95% CI 1.22-2.13).The risk factors significantly associated with de novo UUI were age (RR increased from 1.21, 95% CI 0.74-1.99, at 30-39 years to 6.3, 95% CI 3.85-10.30, at >70 years) and diabetes (RR 1.48, 95% CI 1.05-2.09). CONCLUSIONS The incidence of female UI is 21.2 per 1000 person-years in China. Delivery (vaginal spontaneous delivery, instrumental delivery), high BMI, cigarette smoking, chronic cough, diabetes and older age were risk factors. TWEETABLE ABSTRACT The incidence of female urinary incontinence was 21.2 per 1000 person-years in China. Delivery, BMI, diabetes and old age are risk factors.
Collapse
|
39
|
Qi C, Qin Y, Liu D, Gong J, Ge S, Zhang M, Peng Z, Zhou J, Zhang X, Peng X, Wang H, He C, Xiao J, Li Z, Shen L. 1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1481] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
40
|
Gong J, Shen L, Luo S, Dong Z, Liu D, An S, Xu J, Yang J, Qi Y, Men J, Kong L, Yang Y, Xu T. 1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1486] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
41
|
Aguilar M, Cavasonza LA, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen. PHYSICAL REVIEW LETTERS 2021; 127:021101. [PMID: 34296911 DOI: 10.1103/physrevlett.127.021101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/30/2021] [Accepted: 06/01/2021] [Indexed: 06/13/2023]
Abstract
We report the properties of sodium (Na) and aluminum (Al) cosmic rays in the rigidity range 2.15 GV to 3.0 TV based on 0.46 million sodium and 0.51 million aluminum nuclei collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. We found that Na and Al, together with nitrogen (N), belong to a distinct cosmic ray group. In this group, we observe that, similar to the N flux, both the Na flux and Al flux are well described by the sums of a primary cosmic ray component (proportional to the silicon flux) and a secondary cosmic ray component (proportional to the fluorine flux). The fraction of the primary component increases with rigidity for the N, Na, and Al fluxes and becomes dominant at the highest rigidities. The Na/Si and Al/Si abundance ratios at the source, 0.036±0.003 for Na/Si and 0.103±0.004 for Al/Si, are determined independent of cosmic ray propagation.
Collapse
|
42
|
Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, Raghu VK, Gongora C, Sise ME, Alvi RM, Zubiri L, Nohria A, Sullivan R, Reynolds KL, Zlotoff D, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer 2021; 9:jitc-2021-002771. [PMID: 34145031 PMCID: PMC8215235 DOI: 10.1136/jitc-2021-002771] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/08/2021] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors (ICIs). METHODS This was a retrospective study at a single academic center that compared 2842 consecutive patients who received ICIs with 2699 age- and cancer-type matched patients with metastatic disease who did not receive ICI. A pericardial event was defined as a composite outcome of pericarditis and new or worsening moderate or large pericardial effusion. The endpoints were obtained through chart review and were blindly adjudicated. To identify risk factors associated with a pericardial event, we compared patients who developed an event on an ICI with patients treated with an ICI who did not develop a pericardial event. Cox proportional-hazard model and logistical regression analysis were performed to study the association between ICI use and pericardial disease as well as pericardial disease and mortality. An additional 6-week landmark analysis was performed to account for lead-time bias. RESULTS There were 42 pericardial events in the patients treated with ICI (n=2842) over 193 days (IQR: 64-411), yielding an incidence rate of 1.57 events per 100 person-years. There was a more than fourfold increase in risk of pericarditis or a pericardial effusion among patients on an ICI compared with controls not treated with ICI after adjusting for potential confounders (HR 4.37, 95% CI 2.09 to 9.14, p<0.001). Patients who developed pericardial disease while on an ICI had a trend for increased all-cause mortality compared with patients who did not develop a pericardial event (HR 1.53, 95% CI 0.99 to 2.36, p=0.05). When comparing those who developed pericardial disease after ICI treatment with those who did not, a higher dose of corticosteroid pre-ICI (>0.7 mg/kg prednisone) was associated with increased risk of pericardial disease (HR 2.56, 95% CI 1.00 to 6.57, p=0.049). CONCLUSIONS ICI use was associated with an increased risk of development of pericardial disease among patients with cancer and a pericardial event on an ICI was associated with a trend towards increase in mortality.
Collapse
|
43
|
Drobni Z, Murphy S, Alvi R, Lee C, Gong J, Mosarla R, Rambarat P, Hartmann S, Gilman H, Zubiri L, Raghu V, Sullivan R, Zafar A, Zlotoff D, Dougan M, Sise M, Guidon A, Reynolds K, Neilan T. ASSOCIATION BETWEEN INCIDENTAL STATIN USE AND SKELETAL MYOPATHIES IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)04641-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Cao D, Chu L, Xu Z, Gong J, Deng R, Wang B, Zhou S. Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-κB signaling. Hum Exp Toxicol 2021; 40:1646-1655. [PMID: 33823623 DOI: 10.1177/09603271211006168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Visfatin acts as an oncogenic factor in numerous tumors through a variety of cellular processes. Visfatin has been revealed to promote cell migration and invasion in gastric cancer (GC). Snai1 is a well-known regulator of EMT process in cancers. However, the relationship between visfatin and snai1 in GC remains unclear. The current study aimed to explore the role of visfatin in GC. METHODS The RT-qPCR and western blot analysis were used to measure RNA and protein levels, respectively. The cell migration and invasion were tested by Trans-well assays and western blot analysis. RESULTS Visfatin showed upregulation in GC cells. Additionally, Visfatin with increasing concentration facilitated epithelial-mesenchymal transition (EMT) process by increasing E-cadherin and reducing N-cadherin and Vimentin protein levels in GC cells. Moreover, endogenous overexpression and knockdown of visfatin promoted and inhibited migratory and invasive abilities of GC cells, respectively. Then, we found that snai1 protein level was positively regulated by visfatin in GC cells. In addition, visfatin activated the NF-κB signaling to modulate snai1 protein expression. Furthermore, the silencing of snai1 counteracted the promotive impact of visfatin on cell migration, invasion and EMT process in GC. CONCLUSION Visfatin facilitates cell migration, invasion and EMT process by targeting snai1 via the NF-κB signaling, which provides a potential insight for the treatment of GC.
Collapse
|
45
|
Pang H, Zhang L, Han S, Li Z, Gong J, Liu Q, Liu X, Wang J, Xia Z, Lang J, Xu T, Zhu L. A nationwide population-based survey on the prevalence and risk factors of symptomatic pelvic organ prolapse in adult women in China - a pelvic organ prolapse quantification system-based study. BJOG 2021; 128:1313-1323. [PMID: 33619817 PMCID: PMC8252658 DOI: 10.1111/1471-0528.16675] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 02/19/2021] [Indexed: 01/22/2023]
Abstract
Objective To determine the prevalence, risk factors and burden of symptomatic pelvic organ prolapse (POP) in adult Chinese women. Design A nationwide cross‐sectional study. Setting Six geographic regions of mainland China. Participants Women aged ≥20 years old were included using a multistage, stratified, cluster sampling method from February 2014 through March 2016. Methods We conducted a nationwide epidemiological survey. ‘Symptomatic POP’ was determined by a screening questionnaire and physical examination. Main outcome measurements Prevalence, odds ratio (OR). Results A total of 55 477 women (response rate, 92.5%; mean age, 45.1 years old) were included. The prevalence of symptomatic POP was 9.6% (95% CI 9.3–9.8%) and it increased with age in each stage (P < 0.05). Symptomatic POP‐Q stage II, which mainly involved anterior compartment prolapse, was the most common (7.52%). Minor/moderate burden of symptomatic POP was the most common, with a prevalence of 9.7% (95% CI 9.5–10.0%). The odds for each type of symptomatic POP increased with age (>50 vs 20‐29 years old in symptomatic POP‐Q stage II or higher, OR increased from 1.34 [95% CI 1.32–1.45] to 7.34 [95% CI 4.34–12.41]) and multiple vaginal deliveries (multiparous [≥3] vs nulliparous in symptomatic POP‐Q stage II or higher, OR increased from 1.91 [1.71–2.13] to 2.78 [2.13–3.64]). Conclusions We found a lower prevalence of symptomatic POP than that found in other surveys. The main type of symptomatic POP was anterior compartment prolapse, indicating that it should be considered first. Older age and multiple vaginal deliveries increased the odds of each type of symptomatic POP. Tweetable abstract The prevalence of female symptomatic pelvic organ prolapse (POP) was 9.6% in China. It is related to old age and multiple vaginal deliveries. The prevalence of female symptomatic pelvic organ prolapse (POP) was 9.6% in China. It is related to old age and multiple vaginal deliveries.
Collapse
|
46
|
Zheng LM, Gong J, Zou Y, Zhang MN, Yu TP, Hou J, Zhou Q, Chen N. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2021; 50:229-235. [PMID: 33677887 DOI: 10.3760/cma.j.cn112151-20200617-00479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Objective: To investigate the clinicopathological and molecular characteristics of the epithelioid glioblastoma (eGBM) with BRAF V600E mutation. Methods: Sixteen cases of eGBM with BRAF V600E mutation diagnosed at the West China Hospital of Sichuan University, China from 2012 to 2019 were collected. Their clinicopathological and molecular characteristics were analyzed. Results: The range of patients' age was from 7 to 61 years (median 31.5 years). There were 4 males and 12 females, with a male to female ratio of 1∶3. Eleven cases were newly diagnosed eGBM and five cases had a previous history of astrocytomas. Most of the tumors were located in the cerebral hemisphere, often in the frontal lobe, with an average diameter of 4.6 cm (2.0-8.0 cm). The tumors were composed of relatively uniform, closely packed epithelioid cells, some showing discohesion, with distinct cell membrane, eosinophilic cytoplasm, eccentric nuclei, distinct nucleoli and mitotic activity. Palisaded/coagulative necrosis was seen in all cases. Glomerular microvascular proliferation was seen in most of the cases, while mono-or multi-nucleated tumor giant cells were seen in some cases. Focal sarcomatoid area was seen in 2 cases, and focal pleomorphic xanthoastrocytoma (PXA)-like area was seen in 3 cases. Immunohistochemistry showed variable positivity for GFAP, Olig2 and p53. The median Ki-67 index was 30% (10%-50%). Only one case lost ATRX protein expression. Sanger sequencing identified the BRAF V600E mutation in all sixteen patients. Five cases also had mutations in the TERT gene promoter. No IDH1 (R132) or IDH2 (R172) mutation was detected. Surgical resection of the tumors was performed for all patients, and 3 patients also received adjuvant radiotherapy and chemotherapy. Follow-up data were available for 15 patients, with a follow-up time of 1-89 months (median 10 months). Among the 15 patients, 7 patients died of disease and another 5 patients had recurrences. The overall survival time of the patients under 35 years of age was significantly longer than that of the patients aged 35 years or older (P=0.014), but their progression-free survival was not statistically different (P=0.232). Conclusions: eGBM with BRAF V600E mutation is more commonly detected in young women than other the populations (i.e. elderly or male). The epithelioid morphology should include rhabdoid meningioma, anaplastic PXA, atypical teratoid/rhabdoid tumor, metastatic tumors, and melanoma in its differential diagnosis. PXA-like area is observed in some eGBM cases, suggesting a relationship of these two types of tumor. eGBM is a high-grade malignant tumor and most of the cases show recurrences or deaths in a short-period time. The younger patients have a relatively better prognosis than the older ones.
Collapse
|
47
|
Liu C, Gong J, Yu H, Liu Q, Wang S, Wang J. P78.02 A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non–Small-Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Tan Z, Lu P, Adewole D, Diarra M, Gong J, Yang C. Iron requirement in the infection of Salmonella and its relevance to poultry health. J APPL POULTRY RES 2021. [DOI: 10.1016/j.japr.2020.09.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
49
|
Aguilar M, Cavasonza LA, Allen MS, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mikhailov VV, Mo DC, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Piandani R, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schulz von Dratzig A, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of Heavy Secondary Fluorine Cosmic Rays: Results from the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2021; 126:081102. [PMID: 33709764 DOI: 10.1103/physrevlett.126.081102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 01/22/2021] [Indexed: 06/12/2023]
Abstract
Precise knowledge of the charge and rigidity dependence of the secondary cosmic ray fluxes and the secondary-to-primary flux ratios is essential in the understanding of cosmic ray propagation. We report the properties of heavy secondary cosmic ray fluorine F in the rigidity R range 2.15 GV to 2.9 TV based on 0.29 million events collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. The fluorine spectrum deviates from a single power law above 200 GV. The heavier secondary-to-primary F/Si flux ratio rigidity dependence is distinctly different from the lighter B/O (or B/C) rigidity dependence. In particular, above 10 GV, the F/Si/B/O ratio can be described by a power law R^{δ} with δ=0.052±0.007. This shows that the propagation properties of heavy cosmic rays, from F to Si, are different from those of light cosmic rays, from He to O, and that the secondary cosmic rays have two classes.
Collapse
|
50
|
Gong J, Wang Y, Shu C. LncRNA CHRF promotes cell invasion and migration via EMT in gastric cancer. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 24:1168-1176. [PMID: 32096147 DOI: 10.26355/eurrev_202002_20168] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Long non-coding RNAs (lncRNAs) have been verified to involve in the development and progression of gastric cancer (GC). However, the expression of lncRNA CHRF level in GC has not been mentioned before. Here, we focused on the function of lncRNA CHRF played in GC. PATIENTS AND METHODS A total of 103 GC tissues and paired para-tumor tissues from GC patients were collected. The quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was applied to measure the lncRNA CHRF level in these samples and GC cell lines. The Wound-healing experiment, transwell assay, and Matrigel assay were employed to study the migration and invasion abilities of GC cells. The underlying molecular of lncRNA CHRF was measured using Western-blot. RESULTS LncRNA CHRF expression was significantly higher in 103 GC tissue samples compared with the adjacent para-tumor samples. In GC cells, lncRNA CHRF showed increased expression levels than the human fetal gastric epithelial cells (GES-1). Inhibition of lncRNA CHRF reduced the invasion and migration of MKN-7 cells while the over-expression of lncRNA CHRF promoted HGC-27 cells metastasis. Furthermore, we found that lncRNA CHRF could promote the progression of epithelial-mesenchymal transition (EMT) to promote the GC cell metastasis. CONCLUSIONS Our current study demonstrated that lncRNA CHRF functioned as an oncogene in GC and promoted cell invasion and migration via EMT. This might furnish a potential target for the GC biological diagnosis and therapy.
Collapse
|